Annual SG&A
$6.73 M
+$514.80 K+8.28%
31 December 2023
Summary:
Inhibikase Therapeutics annual selling, general & administrative expenses is currently $6.73 million, with the most recent change of +$514.80 thousand (+8.28%) on 31 December 2023. During the last 3 years, it has risen by +$4.11 million (+156.63%). IKT annual SG&A is now at all-time high.IKT Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$1.64 M
-$337.10 K-17.07%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly selling, general & administrative expenses is currently $1.64 million, with the most recent change of -$337.10 thousand (-17.07%) on 30 September 2024. Over the past year, it has increased by +$14.70 thousand (+0.91%). IKT quarterly SG&A is now -19.39% below its all-time high of $2.03 million, reached on 30 June 2019.IKT Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$297.25 M
-$19.57 M-7.05%
30 September 2024
Summary:
Inhibikase Therapeutics TTM selling, general & administrative expenses is currently -$297.25 million, with the most recent change of -$19.57 million (-7.05%) on 30 September 2024. Over the past year, it has dropped by -$303.92 million (-4552.64%). IKT TTM SG&A is now -2339.73% below its all-time high of $7.04 million, reached on 30 September 2024.IKT TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.3% | +0.9% | -4552.6% |
| 3 y3 years | +156.6% | -0.4% | -5055.1% |
| 5 y5 years | +167.6% | +52.5% | -7773.7% |
IKT Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +156.6% | -19.4% | +21.8% | -282.2% | at low |
| 5 y | 5 years | at high | +167.6% | -19.4% | +342.2% | -2339.7% | at low |
| alltime | all time | at high | +167.6% | -19.4% | +342.2% | -2339.7% | at low |
Inhibikase Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.64 M(-17.1%) | $7.04 M(+0.2%) |
| June 2024 | - | $1.97 M(-2.8%) | $7.03 M(+2.8%) |
| Mar 2024 | - | $2.03 M(+45.0%) | $6.84 M(+1.6%) |
| Dec 2023 | $6.73 M(+8.3%) | $1.40 M(-13.7%) | $6.73 M(+0.8%) |
| Sept 2023 | - | $1.62 M(-9.0%) | $6.68 M(+1.3%) |
| June 2023 | - | $1.78 M(-7.4%) | $6.59 M(+1.8%) |
| Mar 2023 | - | $1.93 M(+43.2%) | $6.47 M(+4.1%) |
| Dec 2022 | $6.22 M(-4.5%) | $1.34 M(-12.6%) | $6.22 M(-4.7%) |
| Sept 2022 | - | $1.54 M(-7.5%) | $6.53 M(-1.6%) |
| June 2022 | - | $1.66 M(-0.3%) | $6.63 M(+0.8%) |
| Mar 2022 | - | $1.67 M(+1.0%) | $6.58 M(+1.1%) |
| Dec 2021 | $6.51 M | $1.65 M(+0.5%) | $6.51 M(+8.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $1.64 M(+2.2%) | $6.00 M(+21.6%) |
| June 2021 | - | $1.61 M(+0.5%) | $4.93 M(+33.5%) |
| Mar 2021 | - | $1.60 M(+39.9%) | $3.70 M(+40.9%) |
| Dec 2020 | $2.62 M(-38.5%) | $1.14 M(+97.0%) | $2.62 M(+40.0%) |
| Sept 2020 | - | $580.80 K(+56.8%) | $1.87 M(-20.8%) |
| June 2020 | - | $370.30 K(-29.8%) | $2.37 M(-41.2%) |
| Mar 2020 | - | $527.70 K(+33.7%) | $4.03 M(-5.6%) |
| Dec 2019 | $4.27 M(+69.6%) | $394.60 K(-63.3%) | $4.27 M(+10.2%) |
| Sept 2019 | - | $1.07 M(-47.1%) | $3.87 M(+38.4%) |
| June 2019 | - | $2.03 M(+164.5%) | $2.80 M(+264.5%) |
| Mar 2019 | - | $768.00 K | $768.00 K |
| Dec 2018 | $2.52 M | - | - |
FAQ
- What is Inhibikase Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual SG&A year-on-year change?
- What is Inhibikase Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly SG&A year-on-year change?
- What is Inhibikase Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics TTM SG&A year-on-year change?
What is Inhibikase Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of IKT is $6.73 M
What is the all time high annual SG&A for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual selling, general & administrative expenses is $6.73 M
What is Inhibikase Therapeutics annual SG&A year-on-year change?
Over the past year, IKT annual selling, general & administrative expenses has changed by +$514.80 K (+8.28%)
What is Inhibikase Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of IKT is $1.64 M
What is the all time high quarterly SG&A for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly selling, general & administrative expenses is $2.03 M
What is Inhibikase Therapeutics quarterly SG&A year-on-year change?
Over the past year, IKT quarterly selling, general & administrative expenses has changed by +$14.70 K (+0.91%)
What is Inhibikase Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of IKT is -$297.25 M
What is the all time high TTM SG&A for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high TTM selling, general & administrative expenses is $7.04 M
What is Inhibikase Therapeutics TTM SG&A year-on-year change?
Over the past year, IKT TTM selling, general & administrative expenses has changed by -$303.92 M (-4552.64%)